Quality of Life in Schizophrenic Patients

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00597168
First received: November 28, 2007
Last updated: June 8, 2010
Last verified: June 2010
  Purpose

This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.


Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: QUALITY: A Non-interventional Study Evaluating Quality Of Life in Schizophrenic Patients Treated With Atypical Antipsychotics, in the Ambulatory Setting. A 9-month, Observational, Multicentric Prospective Study.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change from baseline of QOL assessed by the SWN-K after 9 months of treatment with AAPs. [ Time Frame: 9 months ]

Enrollment: 124
Study Start Date: October 2007
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Ambulatory patients

Criteria

Inclusion Criteria:

  • Patients diagnosed with Schizophrenia treated with atypical antipsychotics (ambulatory patients).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00597168

Locations
Belgium
Research Site
Aalst, Belgium
Research Site
Asse, Belgium
Research Site
Bertrix, Belgium
Research Site
Bierbeek, Belgium
Research Site
Boechout, Belgium
Research Site
Bon-secours, Belgium
Research Site
Bruxelles, Belgium
Research Site
Dendermonde, Belgium
Research Site
Diest, Belgium
Research Site
Duffel, Belgium
Research Site
Eeklo, Belgium
Research Site
Elsene, Belgium
Research Site
Embourg, Belgium
Research Site
Floreffe, Belgium
Research Site
Gent, Belgium
Research Site
Halle, Belgium
Research Site
Henri-Chapelle, Belgium
Research Site
Herstal, Belgium
Research Site
Jambes, Belgium
Research Site
Kortenberg, Belgium
Research Site
Kortrijk, Belgium
Research Site
La Louviere, Belgium
Research Site
Leut, Belgium
Research Site
Leuven, Belgium
Research Site
Libramont, Belgium
Research Site
Liege, Belgium
Research Site
Lierneux, Belgium
Research Site
Melle, Belgium
Research Site
Menen, Belgium
Research Site
Mol, Belgium
Research Site
Mons, Belgium
Research Site
Oostende, Belgium
Research Site
Ottignies, Belgium
Research Site
Roeselare, Belgium
Research Site
Schaerbeek, Belgium
Research Site
Sint-Kruis (Brugge), Belgium
Research Site
Sint-Lambrechts-Woluwe, Belgium
Research Site
Sint-Michiels, Belgium
Research Site
Sint-Niklaas, Belgium
Research Site
Sint-Truiden, Belgium
Research Site
Sleidinge, Belgium
Research Site
Tielt, Belgium
Research Site
Tienen, Belgium
Research Site
Veurne, Belgium
Research Site
Waregem, Belgium
Research Site
Woluwe-Saint-Lambert, Belgium
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Prof Vermylen UZ Leuven
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00597168     History of Changes
Other Study ID Numbers: NIS-NBE-SER-2006/1
Study First Received: November 28, 2007
Last Updated: June 8, 2010
Health Authority: Belgium: Institutional Review Board

Keywords provided by AstraZeneca:
Schizophrenia
atypical antipsychotic
quality of life
ambulatory setting

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 17, 2014